Low expression of NCOA3/SRC3 protein in ovarian cancer tissues, as compared with high expression, was associated with better prognosis in patients undergoing carboplatin monotherapy (P < 0.001), but not in those undergoing combined carboplatin and paclitaxel therapy (P > 0.05) [102]. The gene discussed is NCOA3; the disease is ovarian cancer.